Skip to main content
. 2020 Jun 17;27(12):3289–3306. doi: 10.1038/s41418-020-0578-0

Fig. 5. vIRF1 protects CDCP1 from palmitoylation-dependent degradation by inhibiting CD82.

Fig. 5

a Western blotting analysis of CD82 and CDCP1 expression in HUVECs transduced with 2 MOI lentiviral vIRF1 (vIRF1) or control lentivirus (pHAGE). b Western blotting analysis of CDCP1 expression in vIRF1-expressing HUVECs transduced with lentiviral CD82 (CD82-His). c qPCR analysis of CDCP1 expression in vIRF1-expressing HUVECs transduced with lentiviral CD82 (CD82-His). d Western blotting analysis of CDCP1 expression in vIRF1-expressing HUVECs treated with CHX (80 μg/ml) for 0, 4, 8, and 16 h. e Results were quantified in d. f Western blotting analysis of CDCP1 expression in vIRF1-expressing HUVECs treated with MG132 (25 μM) for 8 h. g Results were quantified in b. h, i Immunoprecipitation analyses of the interaction between CD82 and CDCP1. The light chain band was used as a control to show the equal amounts of antibodies used for immunoprecipitations. j Immunofluorescence analysis (IFA) of the localization of CDCP1 and CD82 in HUVECs. k Acyl-biotinyl exchange assay of the level of palmitoylated CDCP1 in vIRF1-expressing HUVECs transduced with lentiviral CD82. l Quantification of CAM assay of vIRF1-expressing cells transduced with lentiviral CD82. Data were shown as mean ± SD. ***P < 0.001, Student’s t-test. n.s. not significant.